Safety & Efficacy of ALT-711 (Alagebrium) in Chronic Heart Failure

Phase 2

Terminated

• Conditions: Chronic Heart Failure
• Interventions: Drug: Placebo; Drug: ALT-711

• Registration Number: NCT00739687
• Lead Sponsor: Synvista Therapeutics, Inc

Brief Summary

Several lines of evidence have suggested that Advanced Glycation End-products (AGEs) play a role in the development and progression of heart failure. The AGE-crosslink breaker Alagebrium improved cardiac function and symptoms in experimental preclinical and small human heart failure studies. These results have not yet been confirmed in a randomized controlled clinical trial. Objective: to evaluate the safety and efficacy of alagebrium in subjects diagnosed with heart failure. This is a randomized, double-blind, placebo-controlled trial to assess the effects of 400 mg (2 x 100 mg bid) of alagebrium versus placebo over 9 months. 100 subjects will be studied (50 per treatment group) in approximately 6 centers. Procedures: exercise testing (VO2 max; the primary variable), ECGs and blood sampling.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-08
• Study First Submitted: 2008-08-21
• Study First Submitted QC: 2008-08-21
• Study First Posted: 2008-08-22
• Status Verified: 2009-01
• Last Update Submitted: 2009-01-29
• Last Update Posted: 2009-01-30
• Primary Completion: 2009-08
• Study Completion: 2009-10

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• NYHA II-IV heart failure
• Echocardiographic ejection fraction ≤ 45% (echo does not need to be repeated at the screening visit if a prior echo is on record which indicates an ejection fraction < 40%)
• Duration of heart failure > 3 months
• Stable heart failure medical therapy for > 1 month
• Patients need to be able to understand content of and willing to provide informed consent

Exclusion Criteria

• Patient ≤ 18 years
• History of myocardial infarction in previous 6 months
• History of stroke/TIA/RIND in previous 6 months
• Severe valvular dysfunction
• Severe pulmonary disease
• History of systemic inflammatory or collagen vascular disease
• Active and or treated malignancies within 12 months prior to inclusion
• Any significant condition either medical or non-medical that could lead to difficulty complying with the protocol
• Patients on cardiac resynchronisation therapy (CRT) or scheduled for CRT implantation
• Pacemaker therapy (unless rescue pacing at ≤ 40 bpm) or scheduled pacemaker implantation
• History of valve replacement or surgery
• Uncontrolled diabetes mellitus (HbA1c > 9.5%)
• Clinically significant renal disturbance (sMDRD calculated GFR≤30 mL/min/1.73m2; sMDRD is calculated as 186 x serum Cr (mg/dl)-1.154 x years-0.203 x (0.742 if female) x (1.210 if African American)
• Clinically significant liver disease (ASAT/ALAT > 2,5 times the upper limit of normal)
• Severe anemia at baseline (Hemoglobin <10 g/dl or <6.2 mmol/l)
• Use of any investigational drug(s) within 30 days prior to screening
• Pregnancy or active breast-feeding (urine pregnancy tests will be performed on all female subjects of childbearing potential)*
• Active pericarditis/myocarditis
• The inability of patients to undergo exercise testing

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo
ALT-711	ALT-711	Alagebrium 200 mg BID

Primary Outcome Measures

Name	Time	Method
The primary end-point of the study will be aerobic capacity (VO2 max) measured at exercise testing. An improvement of 15% in VO2 max will be considered as a clinically significant increase.	9 months

Trial Locations

Locations (4)

University of Alabama Hospital; 🇺🇸 Birmingham, Alabama, United States

Henry Ford Hospital; 🇺🇸 Detroit, Michigan, United States

Wake Forest University Health Sciences; 🇺🇸 Winston-Salem, North Carolina, United States

Medical University of South Carolina (MUSC); 🇺🇸 Charleston, South Carolina, United States